Toggle Health Problems and D

Pneumonia is increasing (now 1 in 6 child deaths), more vitamin D studies needed – June 2018

Emerging problems in the treatment of paediatric community-acquired pneumonia.

Expert Rev Respir Med. 2018 Jun 8. doi: 10.1080/17476348.2018.1486710. Epub ahead of print
Principi N1, Esposito S2.
1 Università degli Studi di Milano , Milano , Italy.
2 Pediatric Clinic, Department of Surgical and Biomedical Sciences , Università degli Studi di Perugia , Perugia , Italy.

Community-acquired pneumonia (CAP) remains one of the most common reasons for paediatric morbidity and accounts for about 16% of all the deaths occurring in children less than 5 years of age. Areas covered: The main aim of this paper is to discuss the emerging problems for CAP treatment in paediatric age. Expert commentary: Official recommendations for therapeutic approaches to paediatric CAP, despite being not very recent, seem still to be the best solution to assure the highest probabilities of cure for children with this disease living in industrialized countries.
Amoxicillin remains the drug of choice and use of macrolides alone or in combination does not seem supported by solid evidence. Corticosteroids can be useful in CAP associated with bronco-obstruction, whereas their effectiveness in cases with a severe inflammatory response, although plausible, is not supported by data collected through randomized, placebo-controlled trials. Finally, for the administration of vitamin C and vitamin D, the available data are not adequate to draw firm conclusions regarding the real importance of supplementation. Further studies are needed to evaluate which modifications of presently available recommendations for paediatric CAP treatment can improve final prognosis of this still common disease.

PMID: 29883232 DOI: 10.1080/17476348.2018.1486710

Created by admin. Last Modification: Sunday September 16, 2018 14:29:19 GMT-0000 by admin. (Version 3)